1.5604.70% ( +0.070 )
Closed: Nov 12, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is -0.55, above the reasonable range, cheaper than 8.06% of the time in the past 5 years, and the industry ranks 99/257, the industry Median -0.98.
-0.549xP/E
$1.49Stock price
$-2.71Earnings per share
-0.549xP/E
Stock price$1.49Earnings per share$-2.71
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.38x
- Typical range
- -2.18x–-0.74x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03774111148
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
BAYRYUSBayer | -37.68x | -- | $62.64B |
BAYZFUSBayer Aktiengesellschaft | -37.51x | -- | $62.35B |
VTRSUSViatris | -39.72x | 97.55% | $24.14B |
ELANUSElanco Animal Health | -90.04x | 183.61% | $13.24B |
ABVXUSAbivax SA | -17.14x | 22.99% | $7.97B |
AXSMUSAxsome Therap | -49.91x | 29.75% | $7.85B |
CURLFUSCuraleaf Holdings, Inc. | -328.96x | -- | $6.79B |
MANEUSVeraDermics | -63.68x | 97.44% | $6.54B |
VREOFUSVIREO GROWTH INC | -97.28x | -- | $6.40B |
BLTEUSBelite Bio | -61.35x | 29.87% | $6.28B |
LQDAUSLiquidia Tech | -52.47x | 69.38% | $4.94B |
DFTXUSDefinium Therapeutics | -13.72x | 42.85% | $4.63B |
AMLXUSAmylyx Pharmaceuticals | -25.05x | 1.59% | $4.09B |
TARSUSTarsus Pharmaceuticals | -5.39x | 879.07% | $3.78B |
ELVNUSEnliven Therapeutics | -33.20x | 2.84% | $3.77B |
BHCUSBausch Health | -3.72x | 511.90% | $3.13B |
XERSUSXeris Biopharma | -464.63x | -- | $3.02B |
MBXUSMBX Biosciences | -19.16x | 55.43% | $2.78B |
RGCUSRegencell Bioscience | -229.07x | -- | $2.68B |
PHVSUSPharvaris BV | -12.11x | 10.43% | $2.40B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
